Challenges in the Design and Interpretation of Noninferiority Trials

In this review, the authors consider the characteristics and challenges of noninferiority trial designs, including seven essential features of noninferiority trials.

[1]  S. Pocock,et al.  Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. , 2010, The New England journal of medicine.

[2]  S. Pocock,et al.  Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. , 2016, The New England journal of medicine.

[3]  J. Coselli,et al.  Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. , 2014, Journal of the American College of Cardiology.

[4]  Antonio Colombo,et al.  Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. , 2009, The New England journal of medicine.

[5]  M. Mack,et al.  Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. , 2016, The New England journal of medicine.

[6]  M. Porter.  A strategy for health care reform--toward a value-based system. , 2009, The New England journal of medicine.

[7]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[8]  E. Veys,et al.  HL-A AND INFECTIVE SACROILEITIS , 1974 .

[9]  W C Blackwelder,et al.  "Proving the null hypothesis" in clinical trials. , 1981, Controlled clinical trials.

[10]  Michael J. Mack,et al.  Transcatheter versus surgical aortic-valve replacement in high-risk patients. , 2011, The New England journal of medicine.

[11]  J. Leipsic,et al.  Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis , 2016, The Lancet.

[12]  Apixaban versus Warfarin in Patients with Atrial Fibrillation , 2012 .

[13]  Walter Desmet,et al.  ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. , 2015, European heart journal.

[14]  Volkmar Falk,et al.  2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Ca , 2014, European heart journal.

[15]  Laszlo Endrenyi,et al.  Biosimilar Clinical Development – Scientific Considerations and New Methodologies , 2017, Journal of biopharmaceutical statistics.

[16]  R. Little,et al.  The prevention and treatment of missing data in clinical trials. , 2012, The New England journal of medicine.

[17]  S Lange,et al.  Non‐parametric assessment of non‐inferiority with censored data , 2006, Statistics in medicine.

[18]  James R Carpenter,et al.  Non-inferiority trials: are they inferior? A systematic review of reporting in major medical journals , 2016, BMJ Open.

[19]  J. Hartikainen,et al.  Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial , 2016, The Lancet.

[20]  Leon Poller,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[21]  L F Burmeister,et al.  Proving the Null Hypothesis , 1992, Infection Control & Hospital Epidemiology.

[22]  G. Grégoire,et al.  Discrepancies between meta-analyses and subsequent large randomized, controlled trials. , 1997, The New England journal of medicine.

[23]  G. Levine,et al.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Journal of the American College of Cardiology.

[24]  R. D'Agostino,et al.  Non‐inferiority trials: design concepts and issues – the encounters of academic consultants in statistics , 2002, Statistics in medicine.

[25]  Andrew S. Mugglin,et al.  Surgical or Transcatheter Aortic‐Valve Replacement in Intermediate‐Risk Patients , 2017, The New England journal of medicine.

[26]  Helmut Baumgartner,et al.  2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[27]  B. Chaitman,et al.  Comparison of surgical and medical group survival in patients with left main equivalent coronary artery disease. Long-term CASS experience. , 1995, Circulation.

[28]  M. Aguilar,et al.  Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.

[29]  Katherine Odem-Davis,et al.  Some essential considerations in the design and conduct of non-inferiority trials , 2011, Clinical trials.

[30]  S. Windecker,et al.  Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy. , 2015, JACC. Cardiovascular interventions.

[31]  D. Parra,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011 .

[32]  T. Grosser.  Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. , 2017, The New England journal of medicine.

[33]  C. Furberg,et al.  Secondary prevention after myocardial infarction: a review of short-term acute phase trials. , 1983, Progress in cardiovascular diseases.

[34]  S. Pocock,et al.  Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. , 2006, JAMA.

[35]  J. Norrie,et al.  Pragmatic Trials. , 2016, The New England journal of medicine.

[36]  Won Chan Lee,et al.  “Real‐World” Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States , 2015, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.